Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA's Combo Product Consultations To Be Streamlined

This article was originally published in The Pink Sheet Daily

Executive Summary

Internal assessment finds inter-center collaboration stymied by issues ranging from IT compatibility to resource reimbursement, but FDA says it has a five-point plan to improve the process.


Related Content

Combo Product Safety: US FDA Rule On Postmarket Reporting Nears Finalization
FDA 'Intercenter Institutes' Legislation Headed For Senate Mark-Up
Califf Supports Combo Products Pathway At Confirmation Hearing
Senate Bill Aimed At Streamlining Combo Product Regulation
Combo Product Reforms Are A Priority For Next User Fee Round, FDA Officials Say
Human Factors Questions Drive Rise In FDA Inter-Center Consults